This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
FDA Approves Meningococcal Vaccine for Infants, Toddlers
By News Staff
Karen Midthun, M.D., director of the FDA's Center for Biologics Evaluation and Research, said in the agency's news release that the highest rate of meningococcal disease occurs in children younger than 1 year of age.
It is not clear when the CDC's Advisory Committee on Immunization Practices will vote on a recommendation related to the vaccine's expanded approval. The committee's next scheduled meeting is June 22-23.
MCV4 already had been approved by FDA for use in people ages 2 through 55 years. A dose is recommended for children (1-page PDF; About PDFs) at age 11-12 years, with a booster dose at age 16 years. Previously unvaccinated teenagers also are recommended to receive one dose, with a booster dose recommended at age 16 through 18 years for those who received their first dose at age 13-15 years. The vaccine also is recommended for people ages 2-55 years in certain high-risk groups.